Opthea’s Sozinibercept Shows Promise for Wet AMD

Opthea Limited Sponsored ADR (OPT) has released an update.

Opthea Limited announces a new publication supporting the potential of sozinibercept, a treatment for wet age-related macular degeneration (wet AMD), to address unmet needs in retinal disease therapies by targeting VEGF-C/D pathways. The published review in Ophthalmology and Therapy highlights the limitations of current VEGF-A focused treatments and the promise of sozinibercept to improve visual outcomes. Opthea’s Phase 3 clinical trials are well underway, with results from the COAST and ShORe trials expected to bolster sozinibercept’s profile as a first-in-class therapy.

For further insights into OPT stock, check out TipRanks’ Stock Analysis page.